Notable Labs files for bankruptcy, ending ambitions for Boehringer cancer drug

Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the oncology-focused platform company’s decision to file for bankruptcy.

Notable's main focus has been volasertib, a polo-like kinase 1 (PLK1) inhibitor licensed from Boehringer three years ago that was being lined up for a phase 2 study in acute myeloid leukemia. The idea was to use Notable’s own Predictive Medicine Platform to identify patients most likely to benefit from the drug.